{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:23:10Z","timestamp":1780582990290,"version":"3.54.1"},"reference-count":36,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T00:00:00Z","timestamp":1749340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Although benzodiazepines are the first-line treatment for alcohol withdrawal syndrome (AWS), their use may pose significant risks, including oversedation and the potential for misuse, particularly in vulnerable populations such as individuals with alcohol use disorder. Valproate has been investigated as a potential adjunctive treatment for AWS. We first conducted a brief narrative review of the existing literature on valproate in AWS, identifying only a few relevant studies. We then performed a retrospective study to evaluate the effectiveness of valproate, administered orally (PO) or intravenously (IV), in combination with benzodiazepines for the treatment of AWS and associated anxiety symptoms. Methods: We retrospectively analyzed 72 inpatients treated for AWS with valproate (IV or PO) combined with benzodiazepines. Dosages of valproate, the type and daily dose of benzodiazepine, and any adverse effects were recorded. Withdrawal symptoms were assessed using the Clinical Institute Withdrawal Assessment for Alcohol Scale, Revised (CIWA-Ar) on days 1, 3, 5, and 7. Anxiety symptoms were evaluated using the Hamilton Anxiety Rating Scale (HAM-A) on days 1, 3, and 7. Results: The median daily benzodiazepine dose was 2.5 mg lorazepam-equivalents (IQR: 2.0\u20133.81 mg). Significant reductions in both CIWA-Ar and HAM-A scores were observed across all time points. Percentage reductions in both anxiety and withdrawal symptoms were significantly higher in the IV group. No serious adverse events occurred. Conclusions: Valproate appears to be an effective adjunctive treatment for AWS, providing symptom relief and enabling reduced benzodiazepine use. IV administration may offer more rapid clinical improvement. Larger prospective trials are warranted to confirm these findings.<\/jats:p>","DOI":"10.3390\/ph18060855","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:13:01Z","timestamp":1749460381000},"page":"855","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Valproate-Enhanced Protocols for Alcohol Withdrawal Syndrome: A Brief Review and Retrospective Study of Efficacy and the Ability to Reduce Benzodiazepine Use"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3002-529X","authenticated-orcid":false,"given":"Simone","family":"Pardossi","sequence":"first","affiliation":[{"name":"Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9211-5248","authenticated-orcid":false,"given":"Alessandro","family":"Cuomo","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1008-9915","authenticated-orcid":false,"given":"Giacomo","family":"Gualtieri","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Neuroscience, University of Siena, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Pinzi","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuditta","family":"Piumini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5827-0853","authenticated-orcid":false,"given":"Andrea","family":"Fagiolini","sequence":"additional","affiliation":[{"name":"Department of Molecular Medicine, University of Siena School of Medicine, 53100 Siena, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,8]]},"reference":[{"key":"ref_1","unstructured":"Canver, B.R., Newman, R.K., and Gomez, A.E. (2025). Alcohol Withdrawal Syndrome. StatPearls, StatPearls Publishing."},{"key":"ref_2","unstructured":"Attilia, F., Perciballi, R., Rotondo, C., Capriglione, I., Iannuzzi, S., Attilia, M.L., Coriale, G., Vitali, M., Cereatti, F., and Fiore, M. (2018). Alcohol withdrawal syndrome: Diagnostic and therapeutic methods. Riv. Psichiatr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMra1407298","article-title":"Recognition and Management of Withdrawal Delirium (Delirium Tremens)","volume":"371","author":"Schuckit","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","unstructured":"Rahman, A., and Paul, M. (2025). Delirium Tremens(Archived). StatPearls, StatPearls Publishing."},{"key":"ref_5","unstructured":"(2025, May 21). World Health Organization Alcohol. Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/alcohol."},{"key":"ref_6","first-page":"CD005063","article-title":"Benzodiazepines for alcohol withdrawal","volume":"2005","author":"Ntais","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/ADM.0000000000000291","article-title":"\u201cShould Patients with Substance Use Disorders Be Prescribed Benzodiazepines?\u201d No","volume":"11","author":"DuPont","year":"2017","journal-title":"J. Addict. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/fcp.12678","article-title":"Characterization of Benzodiazepine Misuse and Comorbidities in Patients with Alcohol Use Disorder","volume":"35","author":"Lopez","year":"2021","journal-title":"Fundamemntal Clin. Pharma"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/alcalc\/agaa125","article-title":"The Effectiveness of Non-Benzodiazepine, Non-Barbiturate Medications for Alcohol Withdrawal Syndrome: A Rapid Systematic Review","volume":"56","author":"Ghosh","year":"2021","journal-title":"Alcohol Alcohol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/alcalc\/agab057","article-title":"Efficacy and Safety of Anticonvulsants for the Inpatient Treatment of Alcohol Withdrawal Syndrome: A Systematic Review and Meta-Analysis","volume":"57","year":"2022","journal-title":"Alcohol Alcohol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2710.2009.01098.x","article-title":"The Role of Carbamazepine and Oxcarbazepine in Alcohol Withdrawal Syndrome: Carbamazepine and Oxcarbazepine in Alcohol Withdrawal Syndrome","volume":"35","author":"Barrons","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"128","DOI":"10.2165\/00003088-197803020-00003","article-title":"Clinical Pharmacokinetics of Carbamazepine","volume":"3","author":"Bertilsson","year":"1978","journal-title":"Clin. Pharmacokinet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2751","article-title":"Gabapentinoids for Treatment of Alcohol Use Disorder: A Systematic Review and Meta-analysis","volume":"35","author":"Cheng","year":"2020","journal-title":"Hum. Psychopharmacol."},{"key":"ref_14","unstructured":"Rahman, M., Awosika, A.O., and Nguyen, H. (2025). Valproic Acid. StatPearls, StatPearls Publishing."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1300\/J069v21n02_05","article-title":"Divalproex sodium (Depakote) for alcohol withdrawal and relapse prevention","volume":"21","author":"Longo","year":"2002","journal-title":"J. Addict. Dis."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1521-0391.1998.tb00336.x","article-title":"A Pilot Open Randomized Trial of Valproate and Phenobarbital in the Treatment of Acute Alcohol Withdrawal","volume":"7","author":"Rosenthal","year":"1998","journal-title":"Am. J. Addict."},{"key":"ref_17","first-page":"1324","article-title":"Divalproex Sodium in Alcohol Withdrawal: A Randomized Double-Blind Placebo-Controlled Clinical Trial","volume":"25","author":"Reoux","year":"2001","journal-title":"Alcohol Clin. Exp. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/ADA-100100597","article-title":"Divalproex in the Treatment of Alcohol Withdrawal","volume":"26","author":"Myrick","year":"2000","journal-title":"Am. J. Drug Alcohol Abus."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/01.jcp.0000196416.06729.fe","article-title":"Pharmacokinetic Profile of an Oral Loading Dose of Divalproex Sodium During Acute Alcohol Withdrawal","volume":"26","author":"Reoux","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1176\/ajp.153.9.1232a","article-title":"Valproate Treatment of Alcohol Withdrawal and Mania","volume":"153","author":"Hammer","year":"1996","journal-title":"Am. J. Psychiatry"},{"key":"ref_21","first-page":"44","article-title":"Valproate in Anxiety and Withdrawal Syndromes","volume":"50","author":"Ward","year":"1989","journal-title":"J. Clin. Psychiatry"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1017\/S0033291715001014","article-title":"Gender Differences in the Structure of Risk for Alcohol Use Disorder in Adolescence and Young Adulthood","volume":"45","author":"Foster","year":"2015","journal-title":"Psychol. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.35946\/arcr.v40.2.01","article-title":"Gender Differences in the Epidemiology of Alcohol Use and Related Harms in the United States","volume":"40","author":"White","year":"2020","journal-title":"Alcohol Res. Curr. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.drugalcdep.2019.04.023","article-title":"Differences in Alcohol Use Between Younger and Older People: Results from a General Population Study","volume":"202","author":"Veerbeek","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1185\/030079905X48401","article-title":"Benzodiazepines and Anxiety Disorders: A Review for the Practicing Physician","volume":"21","author":"Kaplan","year":"2005","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41398-018-0206-7","article-title":"Effect of Valproate and Pregabalin on Human Anxiety-like Behaviour in a Randomised Controlled Trial","volume":"8","author":"Bach","year":"2018","journal-title":"Transl. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eurpsy.2007.08.001","article-title":"Valproate (Depakine-Chrono) in the Acute Treatment of Outpatients with Generalized Anxiety Disorder without Psychiatric Comorbidity: Randomized, Double-Blind Placebo-Controlled Study","volume":"23","author":"Aliyev","year":"2008","journal-title":"Eur. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of Alcohol Withdrawal: The Revised Clinical Institute Withdrawal Assessment for Alcohol Scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br. J. Addict."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/01.yco.0000165594.60434.84","article-title":"The Diagnosis and Management of Benzodiazepine Dependence","volume":"18","author":"Ashton","year":"2005","journal-title":"Curr. Opin. Psychiatry"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.comppsych.2003.12.007","article-title":"Determination of the Main Risk Factors for Benzodiazepine Dependence Using a Multivariate and Multidimensional Approach","volume":"45","author":"Kan","year":"2004","journal-title":"Compr. Psychiatry"},{"key":"ref_31","first-page":"364","article-title":"A Double-Blind Comparison of the Efficacy and Safety of Lorazepam and Diazepam in the Treatment of the Acute Alcohol Withdrawal Syndrome","volume":"6","author":"Miller","year":"1984","journal-title":"Clin. Ther."},{"key":"ref_32","first-page":"60","article-title":"Comparative Efficacy of Baclofen and Lorazepam in the Treatment of Alcohol Withdrawal Syndrome","volume":"61","author":"Gulati","year":"2019","journal-title":"Indian J. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11606-002-0038-1","article-title":"The Effects of Carbamazepine and Lorazepam on Single versus Multiple Previous Alcohol Withdrawals in an Outpatient Randomized Trial","volume":"17","author":"Malcolm","year":"2002","journal-title":"J. Gen. Intern. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/JNN.0000000000000259","article-title":"Valproic Acid: Special Considerations and Targeted Monitoring","volume":"49","author":"Lowell","year":"2017","journal-title":"J. Neurosci. Nurs."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00213-021-06009-0","article-title":"Effectiveness and Safety of Intravenous Valproate in Agitation: A Systematic Review","volume":"239","author":"Olivola","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.jad.2019.08.071","article-title":"Intravenous Valproate in the Treatment of Acute Manic Episode in Bipolar Disorder: A Review","volume":"260","author":"Fontana","year":"2020","journal-title":"J. Affect. Disord."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/6\/855\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:48:25Z","timestamp":1760032105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/6\/855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,8]]},"references-count":36,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["ph18060855"],"URL":"https:\/\/doi.org\/10.3390\/ph18060855","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,8]]}}}